Hepatocyte Growth Factor to Improve Functioning in PAD
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
HI-PAD is a placebo controlled double-blind randomized pilot clinical trial to determine
whether VM202 may improve walking ability in people with lower extremity peripheral artery
disease (PAD).
Phase:
Phase 2
Details
Lead Sponsor:
Northwestern University
Collaborators:
Helixmith Co., Ltd. National Institute on Aging (NIA)